PT - JOURNAL ARTICLE AU - Stanislas Werfel AU - Carolin E. M. Jakob AU - Stefan Borgmann AU - Jochen Schneider AU - Christoph Spinner AU - Maximilian Schons AU - Martin Hower AU - Kai Wille AU - Martina Haselberger AU - Hanno Heuzeroth AU - Maria M. Rüthrich AU - Sebastian Dolff AU - Johanna Kessel AU - Uwe Heemann AU - Jörg Janne Vehreschild AU - Siegbert Rieg AU - Christoph Schmaderer AU - on behalf of the LEOSS study group TI - Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients AID - 10.1101/2021.02.07.21251260 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.07.21251260 4099 - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251260.short 4100 - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251260.full AB - Scores for identifying patients at high risk of progression of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), are discussed as key instruments for clinical decision-making and patient management during the current pandemic.Here we used the patient data from the multicenter Lean European Open Survey on SARS-CoV-2 - Infected Patients (LEOSS) and applied a technique of variable selection in order to develop a simplified score to identify patients at increased risk of critical illness or death.A total of 1,946 patients, who were tested positive for SARS-CoV-2 were included in the initial analysis. They were split into a derivation and a validation cohort (n=1,297 and 649, respectively). A stability selection among a total of 105 baseline predictors for the combined endpoint of progression to critical phase or COVID-19-related death allowed us to develop a simplified score consisting of five predictors: CRP, Age, clinical disease phase (uncomplicated vs. complicated), serum urea and D-dimer (abbreviated as CAPS-D score). This score showed an AUC of 0.81 (CI95%: 0.77-0.85) in the validation cohort for predicting the combined endpoint within 7 days of diagnosis and 0.81 (CI95%: 0.77-0.85) during the full follow-up. Finally, we used an additional prospective cohort of 682 patients, who were diagnosed largely after the “first wave” of the pandemic to validate predictive accuracy of the score, observing similar results (AUC for an event within 7 days: 0.83, CI95%, 0.78-0.87; for full follow-up: 0.82, CI95%, 0.78-0.86).We thus successfully establish and validate an easily applicable score to calculate the risk of disease progression of COVID-19 to critical illness or death.Competing Interest StatementDr. Spinner reports grants, personal fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, personal fees from Formycon, other from Aperion, other from Eli Lilly, during the conduct of the study; personal fees from AbbVie, personal fees from MSD, grants and personal fees from GSK/ViiV Healthcare, outside the submitted work. Dr. Ruethrich reports grants from IZKF, outside the submitted work. Dr. Vehreschild reports personal fees from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/ Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Aerztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM) and grants from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), (PJ-T: DLR), University of Bristol, Rigshospitalet Copenhagen. All other authors report no conflicts of interest.Clinical TrialDRKS No. DRKS00021145Funding StatementThe LEOSS registry was supported by the German Center for Infection Research (DZIF) and the Willy Robert Pitzer Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study received ethical approval by the ethics board of Klinikum rechts der Isar of the Technical University of Munich, Germany. Approval for LEOSS was obtained by the applicable local ethics committees of all participating centers. A list of all ethics votes is available at https://leoss.net/enrolled-sites-ethic-votes/.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPatient data from the LEOSS registry is subject to the LEOSS Governance, Data Use and Access Policy (policy text available on https://leoss.net).